NCT06095362View on ClinicalTrials.gov

Thyroid Cancer and Central Lymph Node Metastases Detection Using Bevacizumab-IRDye800CW

PHASE1CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

November 29, 2021

Primary Completion Date

October 12, 2023

Study Completion Date

October 12, 2023

Conditions
Thyroid CarcinomaSurgery
Interventions
DRUG

Bevacizumab-IRDye800CW

All patients will receive a dose of Bevacizumab-IRDye800CW, in a dose of 4.5, 10, or 25mg

Trial Locations (1)

9713 GZ

University Medical Center Groningen, Groningen

All Listed Sponsors
collaborator

Dutch Cancer Society

OTHER

lead

University Medical Center Groningen

OTHER